Supported acquisition environment
Supported hardware: Email 1 November 6
exact submission · checked 2026-09-01Confirm currently supported software versions, protocols, and site-specific acquisition configurations.
FDA-cleared profile
FlightPlan for Liver
GE Medical Systems SCS
Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
- Which images or clinical context are in scope? Modality: Fluoroscopy/Angiography Anatomy or clinical context: Liver; hepatic arterial vasculature and hypervascular liver lesions Input: Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.
- Who uses it? Intended users: Physicians.
- What does the software produce? Output: Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
- What is its most important limitation? Key limitation: Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.
Clinical takeaway
Clinical role: Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Evidence takeaway
Evidence from the reviewed source record: FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- Visualizes hepatic vasculature and identifies arteries near hypervascular liver lesions during planning of liver embolization.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
- Intended users
- Physicians.
FDA packet intended-user statement.
- Care setting and population
- Adult
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
- Workflow role
- Detection, localization, or diagnostic support
Conservative normalization of explicit wording in an exact-submission source.
- Required input
- Contrast-injected 3D X-ray angiography or CBCT liver images; other studies may be reviewed side by side but are not the primary catalog modality.
FDA packet primary and secondary image scope.
- Output and human action
- Liver and arterial-tree segmentation and visualization, lesion-vicinity vessel identification, Live Tracking, estimated distal liver region or Virtual Parenchyma, and optional saved or exported results.
FDA packet output scope.
- Limitations
- Adjunct for the planning phase of liver embolization; pediatric applicability is unknown from the supplied FDA packet.
Exact FDA workflow boundary; no pediatric exclusion was stated in the supplied text.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
- FDA submission
- K210807
- Modality
- Fluoroscopy/Angiography
Controlled catalog enum; exact primary input is 3D X-ray angiography/CBCT.
- Anatomy
- Liver; hepatic arterial vasculature and hypervascular liver lesions
Exact FDA anatomy and lesion-vicinity scope.
- Clearance type
- 510(k)
- Decision date
- 2021-10-22
- FDA status
- FDA-cleared
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.
- Deployment and data flow
- On-premise
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for FlightPlan for Liver; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- FDA-reported design-control and bench testing plus clinical assessment of paired CBCT studies by interventional radiologists using a five-point Likert scale; no sensitivity or specificity endpoint was stated.
Submission evidence only.
- Reported sensitivity
- N/A- not diagnostic application
Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.
- Reported specificity
- N/A- not diagnostic application
Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Liver ASSIST Virtual Parenchyma regulatory performance study summary
- DesignStand-Alone Performance
- PopulationAdult
- Scopeexact submission
- Tested versionvxtl_17.0-4.24
- IndependenceIndependence not established
K210807
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K210807 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K210807. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K210807 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K210807: FlightPlan for Liver
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
Liver ASSIST Virtual Parenchyma model card (K210807)
Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K210807
Scope: postmarketSafety
Research history
-
K210807 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K160088
Cydar EV
Cydar Ltd.
Cydar EV provides image guidance by overlaying preoperative 3D vessel anatomy from a previously acquired contrast-enhanced diagnostic CT scan onto live fluoroscopic images to...
- Modality
- Fluoroscopy/Angiography
- Anatomy
- Lower thorax, abdomen, and pelvis; iliac vessels and corresponding veins
- Decision
- 2016-07-07
FDA-cleared K260077
OrthoGrid Hip AI® 4.0
OrthoGrid Systems, Inc.
OrthoGrid Hip AI 4.0 analyzes two-dimensional C-arm fluoroscopic images to assist positioning of hip-replacement components during direct-anterior total hip arthroplasty.
- Modality
- Fluoroscopy/Angiography
- Anatomy
- Hip
- Decision
- 2026-05-29
FDA-cleared K252503
Intelligent NR
Canon, Inc.
Canon Intelligent NR is a noise-reduction function for fluoroscopic images acquired on compatible Canon radiography and fluoroscopy systems.
- Modality
- Fluoroscopy/Angiography
- Anatomy
- Whole body; diagnostic and interventional anatomy
- Decision
- 2026-04-30
FDA-cleared K252099
Trinias
Shimadzu Corporation
Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational,...
- Modality
- Fluoroscopy/Angiography
- Anatomy
- Heart, neurovascular, abdominal, peripheral vessels, and whole body
- Decision
- 2026-03-24